Skip to content
Sonic
AI
Sonic
AI
Home
Discover
Library
Ask Sonic
Projects
Use with Claude or ChatGPT
Show me around
Request source or feature
Can AI Build the First New Pharma Giant in Decades? | Formation Bio CEO Ben Liu, Sonic AI
Home
/
The Heart of Healthcare
/
Can AI Build the First New Pharma Giant in Decades? | Formation Bio CEO Ben Liu
The Heart of Healthcare
Notify me
•
Jul 13, 2026
•
42:55
Interview
Can AI Build the First New Pharma Giant in Decades? | Formation Bio CEO Ben Liu
From
Heart of Healthcare Podcast
Hallie
(Host)
•
Michael Ha
(Analyst, Baird)
•
Ben Liu
(CEO, Formation Bio)
Get the full transcript next time The Heart of Healthcare releases an episode
Summary, key quotes, top claims, and the searchable transcript - emailed automatically. No card needed.
Sign up
Executive Summary
The primary bottleneck in the pharmaceutical industry is not drug discovery, which is becoming more efficient with AI, but the expensive and slow process of clinical development.
Formation Bio's strategy is to acquire promising, already-discovered drug assets and use its proprietary technology platform to run clinical trials more efficiently, capturing value at the development stage.
The 'Uneven Frontiers' framework posits that AI will impact discovery first, then toxicology, and clinical efficacy last, reinforcing the long-term strategic importance of mastering clinical development.
Following the massive success of GLP-1s, the next major therapeutic category is predicted to be 'healthspan' drugs that focus on regeneration and prevention, such as cartilage repair and muscle mass improvement.
Continue your research
Keep pulling the thread on Ben Liu.
The Drug Development Bottleneck
AI's Uneven Impact on Pharma
12
quotes
Transcript
Key Arguments
Analysis
Quotes & Entities
12
Related
Loading transcript...
Processed Jul 13, 2026
Daily intelligence brief →
yt-dlp + mlx-whisper + Gemini